Research advances of IDH gene mutation and AML.
10.7534/j.issn.1009-2137.2014.05.058
- Author:
Ming-Dong SUN
1
;
Yong-Qin ZHENG
2
Author Information
1. Department of Hematology, Binzhou People's Hospital Affiliated to Binzhou Medical College, Binzhou 256610, Shandong Province, China. E-mail: haocheng520@126.com.
2. Department of Hematology, Binzhou People's Hospital Affiliated to Binzhou Medical College, Binzhou 256610, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Isocitrate Dehydrogenase;
genetics;
Leukemia, Myeloid, Acute;
genetics;
Mutation;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(5):1485-1489
- CountryChina
- Language:Chinese
-
Abstract:
The isocitrate dehydrogenase (IDH) gene mutation has been recently found, which may be involved in the occurrence of leukemia. The incidence of IDH gene mutation in the patients with adult acute myeloid leukemia (AML) is high, especially in the AML patients with normal karyotype. Different subtype and molecular biology of IDH display a different effect on the AML prognosis. This gene mutation is related with treatment response, residual, recurrence of leukemia, and it could be a sign of test and a monitoring tool of minimal residual disease (MRD). The IDH gene mutation may be an index for predicting prognosis and guiding therapy. In this article, the research progress of IDH gene mutation and its correlation with acute myeloid leukemia, especially with the clinical characteristics,are reviewed.
